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Abstract
Background: Association studies have been employed to investigate the relationships between host single
nucleotide polymorphisms (SNPs) and susceptibility to pulmonary Tuberculosis (PTB). However, such candidate
genetic markers have not been widely studied in Chinese population, especially with respect to the disease
development from latent M. tuberculosis infection (LTBI).
Methods: In this case–control study, 44 candidate SNPs were examined in a total of 600 participants (PTB patients,
LTBI controls and healthy controls without M. tuberculosis infection) from Zhengzhou, China. The two groups of
controls were frequency matched on gender and age with PTB patients. Genotyping was carried out by the
Illumina Golden Gate assay.
Results: When comparing PTB patients with LTBI controls but not healthy controls without M. tuberculosis infection,
significant associations with disease development were observed for TLR9 1174 A/G, TLR9 1635 A/G and IFNG
2109G/A. The two loci in TLR9 were in LD in our study population (r2=0.96, D’=1.00). A combined effect of the
genotypes associated with increased risk of PTB (i.e. TLR9 1174G/G and IFNG 2109 A/A) was found when comparing
PTB patients with LTBI controls (p=0.004) but not with healthy controls without infection (p=0.433).
Conclusions: Potential associations between TLR9 and IFN-γ genetic polymorphisms and PTB were observed in a
Chinese population which supports further study of the roles played by TLR9/IFN-γ pathway during the development of PTB.
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Background
It is estimated that one third of the world’s population is
infected with Mycobacterium tuberculosis (M. tuberculosis,
MTB), however, only a minority (10%) of those infected
will develop tuberculosis (TB) during their lifetime [1,2].
This clinical diversity on disease susceptibility suggests
that factors other than bacterial infection alone determine
TB development. Apart from socio-economic factors and
virulence of the pathogen, host genetic polymorphism has
been thought to play an important role in determining TB
susceptibility [3-5]. Association studies have been widely
employed to investigate the relationships between TB and
candidate genetic markers, and have been comprehen-
sively reviewed previously [6-9]. Most such studies de-
signed to compare genotype frequencies between TB
patients and unrelated healthy controls without MTB in-
fection [10,11]. However, it is unclear whether an associ-
ation implies susceptibility for developing active disease or
just acquisition of MTB infection by such study design.
Actually, host genetic polymorphisms determining out-
comes of infection are more important for identification
of high-risk infected people susceptible to develop TB. To
employ subjects with latent MTB infection (LTBI) as con-
trols should be a reasonable way to achieve such study ob-
jectives [10,12].
In 2010, there were about 8.8 million incident cases of
TB around the world, and China has the world’s second
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largest number of incident cases (0.9–1.2 million)
(Treatment of Tuberculosis: Guidelines for National Pro-
grammes. World Health Organization, 2011). High-risk
population identification is crucial for diseases preven-
tion and early diagnosis. Besides to assess potential gen-
etic markers, association study also contributes to clarify
potential mechanisms underlying host defense to the
disease development [13]. However, such studies ad-
dressing host genetic susceptibility to TB have not been
widely conducted in China. In previous studies, several
polymorphisms in the inflammatory genes, such as IL-
18, TNF-α and NRAMP1 have been found to be associ-
ated with susceptibility to TB in Chinese population
[14-16]. Whereas all of these studies employed healthy
controls with uncertain MTB infection status and the
amount of studied candidate single nucleotide polymor-
phisms (SNPs) were limited.
We therefore conducted the present study to assess
the impacts of most widely studied SNPs, which have
been studied in the other populations based on literature
review, on host susceptibility to TB in Chinese. Both
healthy controls without MTB infection and LTBI con-




This study was reviewed and approved by the Ethics
Committee of the Institute of Pathogen Biology (Chinese
Academy of Medical Sciences & Peking Union Medical
College). Written informed consent to participate in this
study and to provide 8 mL blood for research was ob-
tained from each study participant before the interview
and testing.
Study population
In this case–control study, participants were recruited be-
tween September 2010 and February 2011 in Zhengzhou
(capital city of Henan Province), China. Two hundred par-
ticipants were recruited in each of the following three
groups: patients with PTB, LTBI controls and healthy con-
trols without MTB infection.
Newly diagnosed PTB patients, since September
2010, were enrolled from the outpatient tuberculosis
clinic in Henna Provisional Infectious Disease Hospital
(Zhengzhou). Eligibility criteria for case patients included:
1) ≥ 18 years old; 2) registered residence in Zhengzhou; 3)
diagnosis of PTB based on clinical evaluation and labora-
tory tests (include chest X-ray, sputum smear microscopy
and culture) according to the Guidelines for Implement-
ing the Prevention and Control of Tuberculosis in China
(2008, Department of Disease Control of Ministry of
Health). Exclusion criteria included malignancy and diag-
nosis of extra-pulmonary TB cases.
Healthy controls without MTB infection and LTBI
controls were registered residence in Zhengzhou and
above 18 years of age. Both groups of controls were se-
lected from participants of the general health examin-
ation and frequency matched with PTB patients on
gender and 5-year age group. Healthy controls without
MTB infection were tuberculin skin test (PPD test)
negative (< 10 mm induration) and without evidence of
active TB and history of TB. LTBI controls, without evi-
dence of active TB and history of TB, should have a
positive PPD test with diameter of the induration ≥15
mm to minimize the misclassification cased by vaccin-
ation with Bacille Calmette Guerin (BCG) [17]. Exclu-
sion criteria for both control groups were the same as
for the case group.
Questionnaire
A questionnaire (please refer to Additional file 1), col-
lecting information on socio-demographic characteris-
tics, medical history, health status, family history and
lifestyle factors, was completed by every participant
under administration by a trained interviewer. Each
study participant was assigned a unique code that was
used to link the questionnaire and specimens.
SNP selection and genotyping
The 44 target SNPs from 32 genes (see Additional file
2), which has been proposed to be associated with host
susceptibility to TB in other populations, were selected
based on literature review of the previous studies. To
guarantee our study had 80% power to detect a positive
association with an odds ratio (OR) of 2.0 (two-sided
testing at α=0.05) given a sample size of 200 in each
study group, it was considered that minor allele fre-
quency of selected SNP should ≥0.15 refer to the allele
frequencies in Asians from dbSNP database of the Na-
tional Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/snp/).
Blood samples were collected from each participant.
Genomic DNA was isolated from Buffy coat cells by
QIAamp DNA Blood mini kit (QIAGEN, Milan, Italy).
Selected SNPs were genotyped by the Illumina Golden-
Gate Genotyping Assay on an Illumina BeadXpress Sys-
tem. All of the assessed SNPs qualified for inclusion.
Genotyping efficiency for the SNPs was between 97%
and 100%. Duplicate SNPs were assessed in 27 samples
and no errors were detected.
Statistical analysis
Differences in the distribution of demographic variables
and lifestyle factors between the three groups were
assessed by chi-square tests. Hardy-Weinberg Equilib-
rium (HWE) in healthy controls without MTB infection
was tested using asymptotic Pearson’s chi-square tests
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for each SNP. SNPs not in HWE were excluded in the
data analyses. The chi-square tests were used to compare
genotype frequencies of PTB patients with LTBI controls
and healthy controls without MTB infection, respectively.
Unconditional logistic regression analysis was used to esti-
mate OR and corresponding 95% confidence intervals (CI)
for disease development using co-dominant, dominant
and recessive models for each SNP, respectively, adjusting
for age and sex. In additional sensitivity analyses, the asso-
ciations of the target SNPs were additionally adjusted for
demographic factors which significantly related to TB in
the study participants. Linkage disequilibrium (LD) was
assessed by Linkage Disequilibrium Analyzer software
[18]. To estimate the combined impact of the identified
individual SNPs, odds of disease development were further
assessed. We performed these tests on the multiplicative
model, and the impact of the genotype associated with in-
creased PTB risk was evaluated. All statistical analyses
were carried out using SAS statistical software, release 9.1.
Results
As shown in Table 1, 200 eligible patients with PTB
were included in this study and the same number of
healthy controls without MTB infection and LTBI con-
trols (frequency matched on sex and 5-year age group)
were enrolled. Half of the study participants (49.8%)
were younger than 30 years, 55.5% of them were males.
Significant differences between PTB patients and both
groups of controls were observed for education (p <
0.01), per capita income in the family (p<0.01), and body
mass index (p<0.01). More smokers (former smokers or
current smokers) were found among PTB patients as
compared with healthy controls without MTB infection
(p < 0.01). As compared to PTB patients, significantly more
subjects were BCG vaccinated among healthy controls
without infection (p < 0.01) and LTBI controls (p < 0.01).
The difference of the number of scars was marginally sig-
nificant between the two groups of controls (p = 0.056).
Genotyping data for all SNPs but one (rs2280788) were
successfully obtained for ≥ 95% of the subjects. The minor
allele frequency was < 5% for 8 assessed SNPs (rs2069778,
rs4986791, rs179008, rs2066844, rs5743708, rs5030729,
rs2066845, rs11574750) and genotype distribution of an-
other 5 selected SNPs was found to be not in HWE in our
study population (rs3764880, rs17235416, rs1800587,
rs2234671; rs1800469). Therefore, after excluding these 14
SNPs, our following analyses were based on genotyping
data of 30 SNPs as shown in Table 2 and Table 3. Geno-
type distribution in PTB patients was compared with LTBI
controls and healthy controls without MTB infection, re-
spectively. No significant difference in genotype distribu-
tion between the study groups was observed for any SNP.
Associations between each SNPs and the development
of PTB were assessed in co-dominant, dominant and
recessive models after control for age and gender. When
comparing PTB patients with LTBI controls but not
healthy controls without MTB infection, significant asso-
ciations with developing disease were observed for TLR9
1174 A/G, TLR9 1635 A/G and IFNG 2109 G/A. As
shown in Table 4, a significant association was observed
for TLR9 1174 A/G with an adjusted OR of 1.87 (95%
CI: 1.08–3.23) (p = 0.027) for G allele carriers when
compared with the more frequent AA genotype carriers.
A significantly increased risk of PTB development was
observed for TLR9 1635 AA genotypes carrying cases
compared with G allele carriers, with an adjusted OR of
1.90 (95% CI: 1.09-3.31) (p = 0.025). These two loci in TLR9
were in LD in our study population (r2 = 0.96, D′= 1.00). In
addition, the GG genotype of IFNG 2109 G/A was found to
be associated with decreased risk of disease development
with an adjusted OR of 0.54 (95% CI: 0.30-0.98) (p = 0.042)
when compared with AA genotype. After additional adjust-
ment for demographic factors which significantly related
with the development of TB as shown in Table 1 (i.e. educa-
tion level, income, body mass index, smoking and the num-
ber of BCG vaccination scars), the associations of the SNPs
were not substantially changed. In the sensitivity analyses,
the findings were not changed as well when not additionally
controlling for smoking which was found not to be signifi-
cantly different between PTB patients and healthy controls
without MTB infection (data not shown). None of the other
SNPs was found to be significantly related to PTB with
respect to LTBI controls or healthy controls without
MTB infection. Due to the space limitation, please
refer to Additional file 3 for the results of association
analyses on the rest SNPs.
The potential combined effect of TLR9 1174 A/G and
IFNG 2109 G/A were investigated as shown in Table 5.
When compare PTB patients with LTBI controls (p =
0.004) but not with healthy controls without MTB infec-
tion (p = 0.433), the combination of genotypes associated
with increased risk of PTB (TLR9 1174 G/G, IFNG 2109
A/A) was found to contribute to disease development.
Discussion
To our knowledge, this is the first large-scale molecular
epidemiological study from China that evaluated host gen-
etic susceptibility to PTB development from LTBI. A total
of 44 selected SNPs in 32 genes were examined for PTB
patients, LTBI controls and healthy controls without MTB
infection, respectively. When comparing PTB patients
with LTBI controls but not healthy controls without MTB
infection, significant associations were observed for TLR9
1174 A/G,TLR9 1635 A/G and IFNG 2109 G/A both indi-
vidually and in a combined effect model.
It is becoming clear that innate immunity plays an im-
portant role in the host defense against MTB infection,
and the first step in this process is recognition of MTB
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[19,20]. Several classes of pattern recognition receptors
(PPRs) are involved in the recognition of MTB by cells
of the innate immune system. Toll-like receptors (TLRs)
are family members of PRRs expressed on macrophages
and other leukocytes [21]. These antigen-presenting cells
recognize and signal in response to microbial ligands
Table 1 Characteristics of the study participants
Variables Total
(N = 600) n* (%)
PTB patients
(N = 200) n* (%)
LTBI controls
(N = 200) n* (%)
Healthy controls without




18–19 years 48 (8.0) 16 (8.0) 15 (7.5) 17 (8.5)
20–24 years 183 (30.5) 61 (30.5) 62 (31.0) 60 (30.0)
25–29 years 68 (11.3) 23 (11.5) 23 (11.5) 22 (11.0)
30–34 years 50 (8.3) 16 (8.0) 16 (8.0) 18 (9.0)
35–39 years 60 (10.0) 20 (10.0) 20 (10.0) 20 (10.0)
40–44 years 48 (8.0) 16 (8.0) 16 (8.0) 16 (8.0)
45–49 years 65 (10.8) 22 (11.0) 22 (11.0) 21 (10.5)
≥50 years 78 (13.0) 26 (13.0) 26 (13.0) 26 (13.0)
Gender
Male 333 (55.5) 111 (55.5) 111 (55.5) 111 (55.5)
Female 267 (44.5) 89 (44.5) 89 (44.5) 89 (44.5)
Education
≤9 years 109 (18.2) 71 (35.5) 16 (8.0) 22 (11.0) <0.01§
10–12 years 139 (23.2) 55 (27.5) 31 (15.5) 53 (26.5) <0.01&
>12 years 352 (58.7) 74 (37.0) 153 (76.5) 125 (62.5)
Per capita income in the family
<500 Yuan/Month 109 (18.2) 59 (29.5) 24 (12.0) 26 (13.0) <0.01§
500-2000 Yuan/Month 254 (42.3) 73 (36.5) 96 (48.0) 85 (42.5) <0.01&
≥2000 Yuan/Month 237 (39.5) 68 (34.0) 80 (40.0) 89 (44.5)
Smoke status
Never smoker 429 (71.5) 131 (65.5) 146 (73.0) 152 (76.0) 0.10§
Former smoker 72 (12.0) 38 (19.0) 23 (11.5) 11 (5.5) <0.01&
Current smoker 99 (16.4) 31 (15.5) 31 (15.5) 37 (18.5)
Current alcohol drinking
No 236 (39.4) 79 (39.5) 86 (43.2) 71 (35.5) 0.45§
Yes 363 (60.0) 121 (60.5) 113 (56.8) 129 (64.5) 0.41&
BMI
≤18.5 (underweight) 78 (12.2) 42 (21.0) 17 (8.5) 14 (7.0) <0.01§
18.5-25 (normal) 412 (68.7) 146 (73.0) 128 (64.0) 138 (69.0) <0.01&
>25 (overweight) 115 (19.2) 12 (6.0) 55 (27.5) 48 (24.0)
Is there TB patient in the family
No 550 (91.8) 179 (89.9) 185 (92.5) 186 (93.0) 0.37§
Yes 49 (8.2) 20 (10.1) 15 (7.5) 14 (7.0) 0.28&
Number of scars by BCG vaccination
0 242 (40.3) 131 (65.5) 66 (33.0) 45 (22.5) <0.01§
1 309 (51.5) 60 (30.0) 117 (58.5) 132 (66.0) <0.01&
≥2 49 (8.2) 9 (4.5) 17 (8.5) 23 (11.5)
Abbreviations: BMI body mass index, LTBI latent M. tuberculosis infection, MTB Mycobacterium tuberculosis; PTB pulmonary tuberculosis, TB tuberculosis.
*Sum may not always add up to total because of missing data.
§p for difference between PTB patients and LTBI controls.
&p for difference between PTB patients and Healthy controls without MTB infeciton.
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Table 2 Genotype distribution of the selected SNPs in the study participants (Part 1/2)
Selected SNP Genotype distribution* p for
differenceSNP (ID) Genotype PTB patients, n (%) LTBI controls n (%) Healthy controls without MTB infection n (%)
IL1RN TT 170 (85.0) 169 (85.8) 173 (88.3) 0.607§
9589 A/T TA 29 (14.5) 28 (14.2) 23 (11.7) 0.432&
(rs454078) AA 1 (0.5) 0 0
IL1B CC 54 (27.0) 63 (32.0) 59 (30.1) 0.270§
−511 C/T CT 96 (48.0) 97 (49.2) 99 (50.5) 0.393&
(rs16944) TT 50 (25.0) 37 (18.8) 38 (19.4)
IL2 TT 89 (44.5) 90 (45.7) 87 (44.4) 0.972§
−330 T/G TG 88 (44.0) 85 (43.2) 88 (44.9) 0.964&
(rs2069762) GG 23 (11.5) 22 (11.2) 21 (10.7)
IL4 TT 120 (60.0) 106 (53.8) 105 (53.6) 0.456§
−589 C/T TC 70 (35.0) 79 (40.1) 77 (39.3) 0.375&
(rs2243250) CC 10 (5.0) 12 (6.1) 14 (7.1)
IL8 AA 74 (37.0) 75 (38.1) 68 (34.7) 0.967§
−251 T/A AT 97 (48.5) 93 (47.2) 99 (50.5) 0.890&
(rs4073) TT 29 (14.5) 29 (14.7) 29 (14.8)
IL8RB TT 83 (41.5) 83 (42.1) 78 (39.8) 0.985§
1208 C/T TC 85 (42.5) 82 (41.6) 88 (44.9) 0.891&
(rs1126579) CC 32 (16.0) 32 (16.2) 30 (15.3)
IL10 TT 99 (49.5) 83 (42.1) 81 (41.3) 0.282§
−819 T/C TC 80 (40.0) 94 (47.7) 87 (44.4) 0.217&
(rs1800871) CC 21 (10.5) 20 (10.2) 28 (14.3)
IL10 TT 176 (88.0) 162 (82.2) 160 (81.6) 0.133§
−1082 A/G TC 23 (11.5) 35 (17.8) 35 (17.9) 0.201&
(rs1800896) CC 1 (0.5) 0 1 (0.5)
IL18 CC 157 (78.5) 147 (74.6) 152 (77.6) 0.648§
−137 G/C CG 40 (20.0) 46 (23.4) 42 (21.4) 0.865&
(rs187238) GG 3 (1.5) 4 (2.0) 2 (1.0)
IL18 CC 58 (29.0) 50 (25.4) 49 (25.0) 0.708§
−607 A/C CA 99 (49.5) 101 (51.3) 101 (51.5) 0.658&
(rs1946518) AA 43 (21.5) 46 (23.4) 46 (23.5)
TLR1 GG 90 (45.2) 90 (35.4) 74 (37.8) 0.325§
−7202 A/G GA 84 (42.2) 91 (32.7) 103 (52.6) 0.117&
(rs5743551) AA 25 (12.6) 16 (8.1) 19 (9.7)
TLR2 TT 97 (48.5) 102 (51.8) 97 (49.5) 0.657§
597 C/T TC 83 (41.5) 73 (37.1) 81 (41.3) 0.956&
(rs3804099) CC 20 (10.0) 22 (11.2) 18 (9.2)
TLR5 CC 189 (94.5) 189 (95.9) 188 (96.4) 0.502§
1174 C/T CT 11 (5.5) 8 (4.1) 7 (3.6) 0.377&
(rs5744168) TT 0 0 0
TLR9 AA 70 (35.0) 67 (34.0) 68 (34.7) 0.051§
1174 A/G AG 89 (44.5) 106 (53.8) 95 (48.5) 0.592&
(rs352139) GG 41 (20.5) 24 (12.2) 33 (16.8)
TLR9 GG 72 (36.0) 70 (35.5) 71 (36.2) 0.052§
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that are bound by the TLRs. As a result, the innate im-
mune system is triggered to produce specific cytokines
to contain or eliminate the microbial infection. Among
the TLR family, TLR1, TLR2, TLR4, TLR8, and TLR9
and their adaptor molecule MyD88 play the most prom-
inent roles in the initiation of the immune response
against MTB [22]. Therefore, as a result, genetic variants
of these TLRs have become biologically plausible candi-
date markers related to host susceptibility. Recently, sig-
nificant associations between TLR9 polymorphisms and
TB disease have been observed in Indonesian [23],
Caucasians and Africans [24]. However, such an asso-
ciation was not observed in a Colombian population
[25]. Our results suggested an association between TLR9
genetic polymorphisms and the development of PTB from
latent infection in Chinese population. TLR9 recognizes
unmethylated CpG motifs in bacterial DNA [26]. It is
worth noting that it has already been demonstrated that
TLR9 recognition modulates the immune response to
MTB and cooperates with TLR2 in mediating optimal
resistance to this bacterium. TLR2/9 knocks out mice
displayed markedly enhanced susceptibility to infection
in association with combined defects in pro-inflammatory
cytokine production in vitro, IFN-γ recall responses
ex vivo, and altered pulmonary pathology [26].
IFN-γ is one of the most widely studied candidate gene
potentially associated with TB susceptibility. Positive associ-
ations with PTB susceptibility have been observed for mul-
tiple SNPs as assessed by individual studies or by means of
meta-analysis in different populations including +874 T/A
[27,28], 2109 A/G [27], -1616 G/A and 3234 T/C [29].
INF-γ is produced predominantly by natural killer and nat-
ural killer T cells as part of the innate immune response,
and by CD4 and CD8 T cells once antigen-specific immun-
ity develop [30]. Convincing evidence for its importance in
controlling MTB infection has been found by both experi-
mental and clinical studies. Subjects defective in the genes
for IFN-γ or IFN-γ receptor have been shown to be prone
for MTB infections [31]. In addition, the increased produc-
tion of IFN-γ post-infection is indicative of the risk of de-
veloping active TB, and local and systemic IFN-γ levels
associate with the severity of the disease [32,33]. Therefore,
these findings suggested important roles of INF-γ both in
infection acquisition and during disease development.
Consistently, our results indicate an increased risk of PTB
development from LTBI for 2109 GG genotype carriage. It
has been suggested that IFNG 2109 G/A polymorphism in-
fluences transcription levels of IFN-γ but the underlying
mechanism is still unclear [34]. The interaction between
SNPs of TLR9 and IFNG further supports a potential role
of TLR9/IFN-γ pathway in active PTB development. Previ-
ous studies provided intriguing information about TLR9
SNPs and Malaria severity [35,36], the association of
TLR9 polymorphisms with altered IFN-γ levels has been
suggested to be potential explanation to TLR9 medi-
ated pathogenesis [37]. However, the association between
TLR9/IFN-γ pathway and TB disease severity has not been
studied. For the first time, out findings provide a clue for
exploring the effects of TLR9/IFN-γ pathway on the devel-
opment of TB beyond controlling of infection acquisition.
It has been discussed that the selection of controls might
partly explain the extensively inconsistency across the gen-
etic association studies on TB susceptibility [10,11]. Recent
studies have suggested some genes may actually be related
to MTB infection but not TB disease development [38,39],
while some other studies have suggested some genes may
differentiate between LTBI and active TB disease [40,41].
Such information is important in completely understanding
the role of these genes in disease pathogenesis and progres-
sion. If controls are latently infected, and there is an associ-
ation seen between a gene and TB, that suggests the gene
influences progression from LTBI to TB. However, if con-
trols are uninfected, the stage specific effect of the genetic
markers on infection acquisition or disease development
(from latent infection to clinical disease) could not be clari-
fied [10]. In our study, significant associations were ob-
served for PTB as compared with LTBI controls but not
healthy controls without MTB infection, which suggested a
positive role of the significant SNPs in developing active
disease. To further investigate the potential influence of the
selection of controls, we analyzed the associations of TLR9/
IFNG SNPs with PTB by combining LTBI controls and
healthy controls without MTB infection together. The re-
sults showed that no statistically significant relation was
found (please refer to Additional file 4). Therefore, only
employing healthy controls with unknown status of MTB
infection or only negatives to infection might cover the ac-
tually existing associations between SNPs and TB disease.
However, it is difficult to truly model the two phenotypes
(infection vs disease) with a case–control study design.
Table 2 Genotype distribution of the selected SNPs in the study participants (Part 1/2) (Continued)
1635 A/G GA 88 (44.0) 104 (52.8) 93 (47.5) 0.608&
(rs352140) AA 40 (20.0) 23 (11.7) 32 (16.3)
Abbreviations: IL interleukin, IL1RN inteleukin 1 receptor antagonist; IL8RB interleukin 8 receptor beta; LTBI latent M. tuberculosis infection; MTB Mycobacterium
tuberculosis, PTB pulmonary tuberculosis, SNP single nucleotide polymorphism, TB tuberculosis, TLR Toll-like receptor.
*Sum may not always add up to total because of missing data.
§p for difference between PTB patients and LTBI controls.
&p for difference between PTB patients and Healthy controls without MTB infection.
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Table 3 Genotype distribution of the selected SNPs in the study participants (Part 2/2)
Selected SNP Genotype distribution* p for
differenceGene SNP (ID) PTB patients, n (%) LTBI controls n (%) Healthy controls without MTB infection n (%)
CCR2 GG 125 (62.5) 125 (63.5) 120 (61.2) 0.397§
190 A/G GA 62 (31.0) 65 (33.0) 67 (34.2) 0.612&
(rs1799864) AA 13 (6.5) 7 (3.6) 9 (4.6)
CCR5 GG 71 (35.5) 62 (31.5) 59 (30.1) 0.511§
59029 A/G GA 97 (48.5) 107 (54.3) 102 (52.0) 0.515&
(rs1799987) AA 32 (16.0) 28 (14.2) 35 (17.9)
RANTES GG 77 (38.5) 63 (32.0) 74 (37.8) 0.349§
−403 G/A GA 96 (48.0) 101 (51.3) 95 (48.5) 0.988&
(rs2107538) AA 27 (13.5) 33 (16.8) 27 (13.8)
MCP1 GG 71 (35.5) 64 (32.5) 75 (38.3) 0.632§
2518 A/G GA 96 (48.0) 104 (52.8) 88 (44.9) 0.812&
(rs1024611) AA 33 (16.5) 29 (14.7) 33 (16.8)
NRAMP1 GG 151 (75.5) 151 (76.7) 139 (70.9) 0.837§
D543N GA 47 (23.5) 43 (21.8) 55 (28.1) 0.582&
(rs17235409) AA 2 (1.0) 3 (1.5) 2 (1.0)
P2X7 AA 116 (58.0) 113 (57.4) 109 (55.6) 0.502§
1513 A/C AC 76 (38.0) 71 (36.0) 76 (38.8) 0.722&
(rs3751143) CC 8 (4.0) 13 (6.6) 11 (5.6)
P2X7 CC 92 (46.2) 86 (43.7) 86 (43.9) 0.835§
−762 T/C CT 81 (40.7) 86 (43.7) 88 (44.9) 0.669&
(rs2393799) TT 26 (13.1) 25 (12.7) 22 (11.2)
TNF-α GG 169 (84.5) 178 (90.4) 176 (89.8) 0.210§
−308 G/A GA 29 (14.5) 18 (9.1) 19 (9.7) 0.284&
(rs1800629) AA =2 (1.0) 1 (0.5) 1 (0.5)
IFNG AA 74 (37.0) 57 (28.9) 73 (37.2) 0.119§
2109 G/A AG 97 (48.5) 99 (50.3) 85 (43.4) 0.374&
(rs1861494) GG 29 (14.5) 41 (20.8) 38 (19.4)
CD4 CC 188 (94.0) 185 (93.9) 184 (93.9) 0.593§
868 C/T CT 11 (5.5) 12 (6.1) 12 (6.1) 0.593&
(rs28919570) TT 1 (0.5) 0 0
CD14 TT 54 (27.1) 66 (33.5) 60 (30.6) 0.331§
159 C/T TC 103 (51.7) 97 (49.2) 104 (53.1) 0.438&
(rs2569190) CC 42 (21.1) 34 (17.3) 32 (16.3)
MBL CC 150 (75.0) 150 (76.1) 141 (71.9) 0.964§
−221 G/C CG 48 (24.0) 45 (22.8) 52 (26.5) 0.742&
(rs7096206) GG 2 (1.0) 2 (1.0) 3 (1.5)
TIRAP CC 196 (98.0) 190 (96.5) 188 (96.4) 0.346§
539 C/T CT 4 (2.0) 7 (3.6) 7 (3.6) 0.359&
(rs8177374) TT 0 0 0
NFKBIA AA 150 (75.0) 148 (75.1) 153 (78.1) 0.999§
−881 A/G AC 48 (24.0) 47 (23.8) 43 (21.9) 0.322&
(rs3138053) CC 2 (1.0) 2 (1.0) 0
NFKBIA CC 149 (74.9) 148 (75.1) 153 (78.1) 0.998§
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Given only 10% of people with LTBI will progress to active
TB, the vast majority of healthy controls would never pro-
gress to active disease. So, the difference between LTBI and
healthy controls is minimal. It is necessary to perform fur-
ther functional studies and prospective studies to verify the
role of TLR9/IFN-γ pathway during the natural history of
TB development.
In the interpretation of our results, some limitations have
to be considered. First, the definition of latent infection
based on tuberculin skin test (TST) could not be claimed
to be perfect especially among the subjects with BCG vac-
cination despite our study participants were adults. As re-
ported that on average 30%-35% will have BCG-related
positive TST results even after an interval of more than 10
to 15 years [42]. Therefore, TST ≥ 15 mm induration, which
should not be attributed to BCG vaccination [43], was used
to define latent infection in our present study to minimize
potential bias caused by misclassification due to BCG vac-
cination. In addition, TST is more suitable for epidemio-
logical studies in recourse limited areas as compared to
Table 3 Genotype distribution of the selected SNPs in the study participants (Part 2/2) (Continued)
−826 C/T CT 48 (24.1) 47 (23.8) 43 (21.9) 0.316&
(rs2233406) TT 2 (1.0) 2 (1.0) 0
Abbreviations: CD cluster of differentiation, CCR chemokine (C-C motif) receptor, IFKBIA NF-kappa-B inhibitor alpha, IFNG Interferon-gamma, MBL mannose binding
lectin, MCP monocyte chemotactic protein, NRAMP natural resistance-associated macrophage protein, LTBI latent M. tuberculosis infection, MTB Mycobacterium tu-
berculosis, PTB pulmonary tuberculosis, RANTES regulated upon activation, normal T-cell expressed, and secreted, SNP single nucleotide polymorphism, TB tubercu-
losis, TLR Toll-like receptor, TNF Tumor necrosis factor.
*Sum may not always add up to total because of missing data.
§p for difference between PTB patients and LTBI controls.
&p for difference between PTB patients and Healthy controls without MTB infection.
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Abbreviations: CI confidence interval, LTBI latent M. tuberculosis infection, MTB Mycobacterium tuberculosis, OR odds ratio, PTB pulmonary tuberculosis, SNP single
nucleotide polymorphism, TB tuberculosis.
*Partly adjusted for age and gender.
&Fully adjusted for age, gender, education level, income, body mass index, number of BCG vaccination scars and smoking.
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Interferon-Gamma Release Assays (IGRA) which are less
influenced by prior BCG vaccination but need more ad-
vanced test settings. Second, considering the very low
prevalence of HIV among TB patients in China (~ 0.9%)
based on our previous systematic review [44], HIV status in
the study participants was not considered. Also, there is a
difficulty to get inform consent for HIV tests in general
population in China due to stigma associated with testing
[45]. Third, selected SNPs were tested in this study, poten-
tial selection bias caused by such candidate genes approach
could not be excluded. In addition, such method was
regarded not as comprehensive and unbiased as Genome-
wide association studies (GWAS). However, rare GWAS
data is available for TB by far. Candidate genes approach is
still cost-effective and useful for association analysis espe-
cially on polymorphisms with low allele frequencies [46].
Fourth, after correcting for multiple testing with the
Bonferroni test as 44 SNPs were tested in the present study,
none of the association observed for TLR9 1174 A/G,TLR9
1635 A/G and IFNG 2109 G/A remains statistically signifi-
cant (p > 0.05/44). Such correction might not be needed
since our study mainly addressed moderately well-
characterized SNPs with previous suggestions of association
with PTB. However, considering this study was conducted
in a different population and the strength of the previous
data is modest, a possibility of false-positive results in our
study could not be completely excluded. Fifth, as the con-
trols were selected from participants of the general health
examination, although from the same city, risks of exposure
to MTB might be different between the two groups of con-
trols and between PTB patients and controls. Therefore,
potential bias caused by selection of controls should be kept
in mind when interpreting our results. Further and larger
studies, preferably large collaborative studies conducted in
different populations, are needed to verify our findings.
Conclusions
In conclusion, potential associations were observed be-
tween TLR9 and IFN-γ genetic polymorphisms and PTB
development from LTBI in a Chinese population. These
epidemiological findings provided clue for further stud-
ies to explore the potential role of TLR9/IFN-γ pathway
in human immune responses to MTB infection and ac-
tive disease development.
Additional files
Additional file 1: The questionnaire used in the study.
Additional file 2: List of selected single nucleotide polymorphisms.
Additional file 3: The association of selected SNPs with the
development of pulmonary tuberculosis.
Additional file 4: The association of TLR9 and IFN-γ SNPs with TB
(PTB patients v.s. combined controls).
Abbreviations
BCG: Bacille Calmette Guerin; GWAS: Genome-wide association studies;
TB: Tuberculosis; HWE: Hardy-Weinberg Equilibrium; IGRA: Interferon-gamma
release assays; LTBI: Latent M. tuberculosis infection; MTB: Mycobacterium
tuberculosis; PTB: Pulmonary tuberculosis; SNPs: Single nucleotide
polymorphisms; TLRs: Toll-like receptors; TST: Tuberculin skin test.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LG and LJM conceived and designed the study; YY and XWL carried out the
study participants’ enrollment, samples collection and tests; JML, FZ, CG, LG,
QH and MFL participated in the questionnaire collection and data
management quality control; WC, XJS and QH participated in study
coordination; YY, LG and JML performed the statistical analysis and wrote
the manuscript; All authors read and approved the final manuscript.
Acknowledgements
The work was supported by the Program for New Century Excellent Talents
in University (NCET-01-0288).
Received: 7 December 2012 Accepted: 28 October 2013
Published: 31 October 2013
References
1. Lawn SD, Zumla AI: Tuberculosis. Lancet 2011, 378(9785):57–72.
2. Meya DB, McAdam KP: The TB pandemic: an old problem seeking new
solutions. J Intern Med 2007, 261(4):309–329.
3. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR: Risk of
tuberculosis from exposure to tobacco smoke: a systematic review and
meta-analysis. Arch Intern Med 2007, 167(4):335–342.





























AA/AG GG/GA 97 (48.5) 122 (61.9) Ref. Ref. 97 (48.5) 103 (52.6) Ref. Ref.
























p for trend 0.004 0.002 0.433 0.697
Abbreviations: CI confidence interval, LTBI latent M. tuberculosis infection, MTB Mycobacterium tuberculosis, OR odds ratio, PTB pulmonary tuberculosis, SNP single
nucleotide polymorphism.
*Partly adjusted for age and gender.
&Fully adjusted for age, gender, education level, income, body mass index, number of BCG vaccination scars and smoking.
Yang et al. BMC Infectious Diseases 2013, 13:511 Page 9 of 10
http://www.biomedcentral.com/1471-2334/13/511
4. Murray M, Oxlade O, Lin HH: Modeling social, environmental and
biological determinants of tuberculosis. Int J Tuberc Lung Dis 2011,
15(Suppl 2):S64–S70.
5. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lonnroth K, Patra
J, Poznyak V, Popova S: The association between alcohol use, alcohol use
disorders and tuberculosis (TB). A systematic review. Bmc Public Health
2009, 9:450.
6. Moller M, Hoal EG: Current findings, challenges and novel approaches in human
genetic susceptibility to tuberculosis. Tuberculosis (Edinb) 2010, 90(2):71–83.
7. Li X, Yang Y, Zhou F, Zhang Y, Lu H, Jin Q, Gao L: SLC11A1 (NRAMP1)
polymorphisms and tuberculosis susceptibility: updated systematic
review and meta-analysis. PLoS One 2011, 6(1):e15831.
8. Gao L, Tao Y, Zhang L, Jin Q: Vitamin D receptor genetic polymorphisms
and tuberculosis: updated systematic review and meta-analysis. Int J
Tuberc Lung Dis 2010, 14(1):15–23.
9. Pacheco AG, Moraes MO: Genetic polymorphisms of infectious diseases in
case–control studies. Dis Markers 2009, 27(3):173–186.
10. Stein CM: Genetic epidemiology of tuberculosis susceptibility: impact of
study design. PLoS Pathog 2011, 7(1):e1001189.
11. Stein CM, Baker AR: Tuberculosis as a complex trait: impact of genetic
epidemiological study design. Mamm Genome 2011, 22(1–2):91–99.
12. Moller M, de Wit E, Hoal EG: Past, present and future directions in human
genetic susceptibility to tuberculosis. FEMS Immunol Med Microbiol 2010,
58(1):3–26.
13. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A:
Biomarkers and diagnostics for tuberculosis: progress, needs, and
translation into practice. Lancet 2010, 375(9729):1920–1937.
14. Han M, Yue J, Lian YY, Zhao YL, Wang HX, Liu LR: Relationship between
single nucleotide polymorphism of interleukin-18 and susceptibility to
pulmonary tuberculosis in the Chinese Han population. Microbiol
Immunol 2011, 55(6):388–393.
15. Ma MJ, Xie LP, Wu SC, Tang F, Li H, Zhang ZS, Yang H, Chen SL, Liu N, Liu
W, et al: Toll-like receptors, tumor necrosis factor-alpha, and interleukin-
10 gene polymorphisms in risk of pulmonary tuberculosis and disease
severity. Hum Immunol 2010, 71(10):1005–1010.
16. Jin J, Sun L, Jiao W, Zhao S, Li H, Guan X, Jiao A, Jiang Z, Shen A: SLC11A1
(Formerly NRAMP1) gene polymorphisms associated with pediatric
tuberculosis in China. Clin Infect Dis 2009, 48(6):733–738.
17. Schluger NW, Burzynski J: Recent advances in testing for latent TB. Chest
2010, 138(6):1456–1463.
18. Ding K, Zhou K, He F, Shen Y: LDA–a java-based linkage disequilibrium
analyzer. Bioinformatics 2003, 19(16):2147–2148.
19. van Crevel R, Ottenhoff TH, van der Meer JW: Innate immunity to
Mycobacterium tuberculosis. Clin Microbiol Rev 2002, 15(2):294–309.
20. Tsolaki AG: Innate immune recognition in tuberculosis infection. Adv Exp
Med Biol 2009, 653:185–197.
21. Jo EK: Mycobacterial interaction with innate receptors: TLRs, C-type lec-
tins, and NLRs. Curr Opin Infect Dis 2008, 21(3):279–286.
22. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R: Innate
immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol
2011, 2011:405310.
23. Kobayashi K, Yuliwulandari R, Yanai H, Naka I, Lien LT, Hang NT, Hijikata M,
Keicho N, Tokunaga K: Association of TLR polymorphisms with
development of tuberculosis in Indonesian females. Tissue Antigens 2011,
79(3):190–197.
24. Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, Myers JL, Estevan R,
Patillo SG, Olesen R, Tacconelli A, et al: Variants in toll-like receptors 2 and
9 influence susceptibility to pulmonary tuberculosis in Caucasians,
African-Americans, and West Africans. Hum Genet 2010, 127(1):65–73.
25. Sanchez D, Lefebvre C, Rioux J, Garcia LF, Barrera LF: Evaluation of Toll-like re-
ceptor and adaptor molecule polymorphisms for susceptibility to tubercu-
losis in a Colombian population. Int J Immunogenet 2012, 39(3):216–223.
26. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A: TLR9 regulates Th1
responses and cooperates with TLR2 in mediating optimal resistance to
Mycobacterium tuberculosis. J Exp Med 2005, 202(12):1715–1724.
27. Etokebe GE, Bulat-Kardum L, Johansen MS, Knezevic J, Balen S, Matakovic-
Mileusnic N, Matanic D, Flego V, Pavelic J, Beg-Zec Z, et al: Interferon-
gamma gene (T874A and G2109A) polymorphisms are associated with
microscopy-positive tuberculosis. Scand J Immunol 2006, 63(2):136–141.
28. Tian C, Zhang Y, Zhang J, Deng Y, Li X, Xu D, Huang H, Huang J, Fan H:
The +874 T/A polymorphism in the interferon-gamma gene and tuberculosis
risk: an update by meta-analysis. Hum Immunol 2011, 72(11):1137–1142.
29. Cooke GS, Campbell SJ, Sillah J, Gustafson P, Bah B, Sirugo G, Bennett S,
McAdam KP, Sow O, Lienhardt C, et al: Polymorphism within the
interferon-gamma/receptor complex is associated with pulmonary tuber-
culosis. Am J Respir Crit Care Med 2006, 174(3):339–343.
30. Schoenborn JR, Wilson CB: Regulation of interferon-gamma during innate
and adaptive immune responses. Adv Immunol 2007, 96:41–101.
31. Ottenhoff TH, Kumararatne D, Casanova JL: Novel human
immunodeficiencies reveal the essential role of type-I cytokines in im-
munity to intracellular bacteria. Immunol Today 1998, 19(11):491–494.
32. Condos R, Rom WN, Liu YM, Schluger NW: Local immune responses
correlate with presentation and outcome in tuberculosis. Am J Respir Crit
Care Med 1998, 157(3 Pt 1):729–735.
33. Ansari A, Talat N, Jamil B, Hasan Z, Razzaki T, Dawood G, Hussain R:
Cytokine gene polymorphisms across tuberculosis clinical spectrum in
Pakistani patients. PLoS One 2009, 4(3):e4778.
34. Henri S, Stefani F, Parzy D, Eboumbou C, Dessein A, Chevillard C:
Description of three new polymorphisms in the intronic and 3’UTR
regions of the human interferon gamma gene. Genes Immun 2002,
3(1):1–4.
35. Mockenhaupt FP, Hamann L, von Gaertner C, Bedu-Addo G, von Kleinsorgen
C, Schumann RR, Bienzle U: Common polymorphisms of toll-like receptors
4 and 9 are associated with the clinical manifestation of malaria during
pregnancy. J Infect Dis 2006, 194(2):184–188.
36. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR,
Otchwemah RN, Dietz E, Ehrhardt S, Schroder NW, et al: Toll-like receptor
(TLR) polymorphisms in African children: common TLR-4 variants predis-
pose to severe malaria. Proc Natl Acad Sci USA 2006, 103(1):177–182.
37. Sam-Agudu NA, Greene JA, Opoka RO, Kazura JW, Boivin MJ, Zimmerman
PA, Riedesel MA, Bergemann TL, Schimmenti LA, John CC: TLR9
polymorphisms are associated with altered IFN-gamma levels in children
with cerebral malaria. Am J Trop Med Hyg 2010, 82(4):548–555.
38. Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD,
Leontiev DV, Thompson CL, Cartier KC, Elston RC, et al: Genome scan of M.
tuberculosis infection and disease in Ugandans. PLoS One 2008,
3(12):e4094.
39. Thye T, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Brattig
NW, Niemann S, Rusch-Gerdes S, Horstmann RD, et al: IL10 haplotype asso-
ciated with tuberculin skin test response but not with pulmonary TB.
PLoS One 2009, 4(5):e5420.
40. Flores-Villanueva PO, Ruiz-Morales JA, Song CH, Flores LM, Jo EK, Montano
M, Barnes PF, Selman M, Granados J: A functional promoter polymorphism
in monocyte chemoattractant protein-1 is associated with increased sus-
ceptibility to pulmonary tuberculosis. J Exp Med 2005, 202(12):1649–1658.
41. Stein CM, Zalwango S, Chiunda AB, Millard C, Leontiev DV, Horvath AL,
Cartier KC, Chervenak K, Boom WH, Elston RC, et al: Linkage and
association analysis of candidate genes for TB and TNFalpha cytokine
expression: evidence for association with IFNGR1, IL-10, and TNF recep-
tor 1 genes. Hum Genet 2007, 121(6):663–673.
42. Menzies R, Vissandjee B: Effect of bacille Calmette-Guerin vaccination on
tuberculin reactivity. Am Rev Respir Dis 1992, 145(3):621–625.
43. Andersen P, Munk ME, Pollock JM, Doherty TM: Specific immune-based
diagnosis of tuberculosis. Lancet 2000, 356(9235):1099–1104.
44. Gao L, Zhou F, Li X, Jin Q: HIV/TB co-infection in mainland China: a meta-
analysis. PLoS One 2010, 5(5):e10736.
45. Beckwith CG, Flanigan TP, Del RC, Simmons E, Wing EJ, Carpenter CC,
Bartlett JG: It is time to implement routine, not risk-based. HIV testing. Clin
Infect Dis 2005, 40(7):1037–1040.
46. Wilkening S, Chen B, Bermejo JL, Canzian F: Is there still a need for
candidate gene approaches in the era of genome-wide association
studies? Genomics 2009, 93(5):415–419.
doi:10.1186/1471-2334-13-511
Cite this article as: Yang et al.: Potential association of pulmonary
tuberculosis with genetic polymorphisms of toll-like receptor 9 and
interferon-gamma in a Chinese population. BMC Infectious Diseases
2013 13:511.
Yang et al. BMC Infectious Diseases 2013, 13:511 Page 10 of 10
http://www.biomedcentral.com/1471-2334/13/511
